Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4561-4567

  Mercorelli, Beatrice ^a   Oreste, Pasqua ^b   Sinigalia, Elisa ^a   Muratore, Giulia ^a   Lembo, David ^c   Palù, Giorgio ^a   Loregian, Arianna ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Glycores 2000 Srl   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BACTERIAL POLYSACCHARIDE; HEPARIN; SULFUR DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL SPREADING; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ESCHERICHIA COLI; HOST CELL; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS PARTICLE; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; BACTERIAL CAPSULES; CELL LINE; CYTOMEGALOVIRUS; ESCHERICHIA COLI; HUMANS; MICE; NIH 3T3 CELLS; SULFATES; VIRION; VIRUS REPLICATION;

EID: 78049307966     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00721-10     Document Type: Article

References (32)

1. Britt, W. 2008. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol. 325:417-470.
2. Casu, B., G. Diamantini, G. Fedeli, M. Mantovani, P. Oreste, R. Pescador, R. Porta, G. Prino, G. Torri, and G. Zoppetti. 1986. Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins. Arzneimittelforschung 36:637-642.
3. Casu, B., and U. Gennaro. 1975. A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr. Res. 39:168-176.
4. Casu, B., G. Grazioli, N. Razi, M. Guerrini, A. Naggi, G. Torri, P. Oreste, F. Tursi, G. Zoppetti, and U. Lindahl. 1994. Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr. Res. 263:271-284.
5. Compton, T. 2004. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell. Biol. 14:5-8.
6. Ghosh, T., K. Chattopadhyay, M. Marschall, P. Karmakar, P. Mandal, and B. Ray. 2009. Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation. Glycobiology 19:2-15.
7. Gordon, M., S. Deeks, C. De Marzo, J. Goodgame, M. Guralnik, W. Lang, T. Mimura, D. Pearce, and Y. Kaneko. 1997. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV)-and cytomegalovirus (CMV)-infected patients: indication of anti-CMV activity with low toxicity. J. Med. 28:108-128.
8. Harden, E. A., R. Falshaw, S. M. Carnachan, E. R. Kern, and M. N. Prichard. 2009. Virucidal activity of polysaccharide extracts from four algal species against herpes simplex virus. Antivir. Res. 83:282-289.
9. Harenberg, J., and J. X. De Vries. 1983. Characterization of heparins by high performance size exclusion liquid chromatography. J. Chromatogr. 261:287-292.
10. Hayashi, K., T. Hayashi, and A. Tomoda. 2008. Phenoxazine derivatives inactivate human cytomegalovirus, herpes simplex virus-1, and herpes simplex virus-2 in vitro. J. Pharmacol. Sci. 106:369-375.
11. Jones, T. R., S. W. Lee, S. V. Johann, V. Razinkov, R. J. Visalli, B. Feld, J. D. Bloom, and J. O'Connell. 2004. Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule. J. Virol. 78:1289-1300.
12. Kari, B., and R. Gehrz. 1992. A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope. J. Virol. 66:1761-1764.
13. Kern, E. R. 1999. Animal models for cytomegalovirus infections: murine CMV, p. 927-934. In O. Zak, M. Sande, C. Carbon, R. Kaninsky, T. O'Reilly, and E. R. Kern (ed.), Handbook on animal models for antimicrobial therapy. Academic Press, London, United Kingdom.
14. Klibanov, O. M. 2009. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection. Curr. Opin. Invest. Drugs. 10:845-859.
15. Kuritzkes, D. R. 2009. HIV-1 entry inhibitors: an overview. Curr. Opin. HIV AIDS 4:82-87.
16. Leali, D., M. Belleri, C. Urbinati, D. Coltrini, P. Oreste, G. Zoppetti, D. Ribatti, M. Rusnati, and M. Presta. 2001. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J. Biol. Chem. 276:37900-37908.
17. Lembo, D., M. Donalisio, M. Rusnati, A. Bugatti, M. Cornaglia, P. Cappello, M. Giovarelli, P. Oreste, and S. Landolfo. 2008. Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob. Agents Chemother. 52:1374-1381.
18. Lischka, P., and H. Zimmermann. 2008. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol. 8:541-548.
19. Loregian, A., and D. M. Coen. 2006. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem. Biol. 13:191-200.
20. Loregian, A., B. Mercorelli, G. Muratore, E. Sinigalia, S. Pagni, S. Massari, G. Gribaudo, B. Gatto, M. Palumbo, O. Tabarrini, V. Cecchetti, and G. Palu. The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein. Antimicrob. Agents Chemother. 54:1930-1940.
21. Luganini, A., A. Giuliani, G. Pirri, L. Pizzuto, S. Landolfo, and G. Gribaudo. Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antivir. Res. 85:532-540.
22. Mocarski, E. S., T. Shenk, and R. F. Pass. 2007. Cytomegaloviruses, p. 2701-2772. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott/The Williams & Wilkins Co., Philadelphia, PA.
23. Pinna, D., P. Oreste, T. Coradin, A. Kajaste-Rudnitski, S. Ghezzi, G. Zoppetti, A. Rotola, R. Argnani, G. Poli, R. Manservigi, and E. Vicenzi. 2008. Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide. Antimicrob. Agents Chemother. 52:3078-3084.
24. Rusnati, M., P. Oreste, G. Zoppetti, and M. Presta. 2005. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr. Pharm. Des. 11:2489-2499.
25. Rusnati, M., E. Vicenzi, M. Donalisio, P. Oreste, S. Landolfo, and D. Lembo. 2009. Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicides. Pharmacol. Ther. 123:310-322.
26. Schmidtke, M., A. Karger, A. Meerbach, R. Egerer, A. Stelzner, and V. Makarov. 2003. Binding of a N,N′-bisheteryl derivative of dispirotripiperazine to heparan sulfate residues on the cell surface specifically prevents infection of viruses from different families. Virology 311:134-143.
27. Shogan, B., L. Kruse, G. B. Mulamba, A. Hu, and D. M. Coen. 2006. Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B. J. Virol. 80:4740-4747.
28. Stinski, M. F., and D. T. Petrik. 2008. Functional roles of the human cytomegalovirus essential IE86 protein. Curr. Top. Microbiol. Immunol. 325: 133-152.
29. Sullivan, V., K. K. Biron, C. Talarico, S. C. Stanat, M. Davis, L. M. Pozzi, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.
30. Sullivan, V., and D. M. Coen. 1991. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J. Infect. Dis. 164:781-784.
31. Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 359:85.
32. Vicenzi, E., A. Gatti, S. Ghezzi, P. Oreste, G. Zoppetti, and G. Poli. 2003. Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. AIDS 17:177-181.